Buchumschlag

Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas

Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Developmen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Boxerman, Jerrold L (VerfasserIn) , Quarles, Chad C (VerfasserIn) , Hu, Leland S (VerfasserIn) , Erickson, Bradley J (VerfasserIn) , Gerstner, Elizabeth R (VerfasserIn) , Smits, Marion (VerfasserIn) , Kaufmann, Timothy J (VerfasserIn) , Barboriak, Daniel P (VerfasserIn) , Huang, Raymond H (VerfasserIn) , Wick, Wolfgang (VerfasserIn) , Weller, Michael (VerfasserIn) , Galanis, Evanthia (VerfasserIn) , Kalpathy-Cramer, Jayashree (VerfasserIn) , Shankar, Lalitha (VerfasserIn) , Jacobs, Paula (VerfasserIn) , Chung, Caroline (VerfasserIn) , van den Bent, Martin J (VerfasserIn) , Chang, Susan (VerfasserIn) , Al Yung, W K (VerfasserIn) , Cloughesy, Timothy F (VerfasserIn) , Wen, Patrick Y (VerfasserIn) , Gilbert, Mark R (VerfasserIn) , Rosen, Bruce R (VerfasserIn) , Ellingson, Benjamin M (VerfasserIn) , Schmainda, Kathleen M (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 09 June 2020
In: Neuro-Oncology
Year: 2020, Jahrgang: 22, Heft: 9, Pages: 1262-1275
ISSN:1523-5866
DOI:10.1093/neuonc/noaa141
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/neuonc/noaa141
Volltext
Verfasserangaben:Jerrold L Boxerman, Chad C Quarles, Leland S Hu, Bradley J Erickson, Elizabeth R Gerstner, Marion Smits, Timothy J Kaufmann, Daniel P Barboriak, Raymond H Huang, Wolfgang Wick, Michael Weller, Evanthia Galanis, Jayashree Kalpathy-Cramer, Lalitha Shankar, Paula Jacobs, Caroline Chung, Martin J van den Bent, Susan Chang, W K Al Yung, Timothy F Cloughesy, Patrick Y Wen, Mark R Gilbert, Bruce R Rosen, Benjamin M Ellingson, and Kathleen M Schmainda, and Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee
Beschreibung
Zusammenfassung:Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition issued an updated consensus DSC-MRI protocol compatible with the standardized brain tumor imaging protocol (BTIP) for high-grade gliomas that is increasingly used in the clinical setting and is the default MRI protocol for the National Clinical Trials Network. After reviewing the basis for controversy over DSC-MRI protocols, this paper provides evidence-based best practices for clinical DSC-MRI as determined by the Committee, including pulse sequence (gradient echo vs spin echo), BTIP-compliant contrast agent dosing (preload and bolus), flip angle (FA), echo time (TE), and post-processing leakage correction. In summary, full-dose preload, full-dose bolus dosing using intermediate (60°) FA and field strength-dependent TE (40-50 ms at 1.5 T, 20-35 ms at 3 T) provides overall best accuracy and precision for cerebral blood volume estimates. When single-dose contrast agent usage is desired, no-preload, full-dose bolus dosing using low FA (30°) and field strength-dependent TE provides excellent performance, with reduced contrast agent usage and elimination of potential systematic errors introduced by variations in preload dose and incubation time.
Beschreibung:Gesehen am 01.03.2021
Beschreibung:Online Resource
ISSN:1523-5866
DOI:10.1093/neuonc/noaa141

Ähnliche Einträge